<DOC>
	<DOCNO>NCT01313858</DOCNO>
	<brief_summary>This study ass use golimumab ( Simponi速 ) participant rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis . The study objective evaluate clinical safety golimumab ( Simponi速 ) real-life , clinical practice condition assess incidence type ( serious ) adverse event change clinical status participant assess clinical parameter .</brief_summary>
	<brief_title>A Study Investigate Use Golimumab ( Simponi速 ) Participants With Rheumatoid Arthritis , Psoriatic Arthritis Ankylosing Spondylitis ( P06554 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Has rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis treatment Simponi速 autoinjector device initiate first time No specific exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>